

Attorney Docket No.: F7683(V)
Serial No.: 10/539,434
Filed: January 13, 2006
Confirmation No.: 6803

INFORMATION DISCLOSURE STATEMENT

Documents relating to the above-identified application are submitted herewith. The following information is intended for the Examiner's information and for citation with the instant case. This submission does not constitute either a representation that a thorough search has been made or an admission that the documents cited herein are properly citable against the above-identified application. Any comments are not intended to take the place of the Examiner's independent consideration of each document. An attached PTO Form 1449 lists these documents.

Please charge any additional fees or credit overpayment to Deposit Account No. 12-1155. (37 CFR 1.97(b)(3))

Respectfully submitted,



Gerard J. McGowan, Jr.
Registration No. 29,412
Attorney for Applicant(s)

GJM/pod
(201) 894-2297

FORM PTO-1449

ATTORNEY DOCKET NO.: F7663(V)

FILING DATE: January 13, 2006

Page -1 of 1-

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

U.S. PATENT DOCUMENTS

EXAMINER INITIALS		DOCUMENT NO.	DATE	NAME OF INVENTOR	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	1	2002/037630 A1	3/02	Berthelsen et al.			
	2	6,207,636 B1	3/01	Portman			
	3	2002/0019334	2/02	Portman			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES OR NO
	4	0 629 350 A	12/94	Europe			
	5	02/15719	2/02	WO			
	6	01/85984	11/01	WO			

OTHER DOCUMENTS

	7	Partial European Search Report on Application No. EP 02 25 8932 dated June 2, 2003
	8	Database WPI, XP002242963 and JP 04 145139 A
	9	Aoyama et al., "Effect of Soy and Milk Whey Protein Isolates and Their Hydrolysates on Weight Reduction in Genetically Obese Mice", Bioscience Biotechnology Biochemistry, Japan Soc. For Biotechnology, Biotechnology and Agrochem., Vol 64, No. 12, December 2000, pp. 2594-2600
	10	D Drucker, published in Current Pharmaceutical Design, 2001, 7, pp. 1399-1412
	11	"Effect of 6-week course of glucagon-like-peptide-1 on glycaemic control, insulin sensitivity and β -cell function in type 2 diabetes" by Zander et al, published in The Lancet, vol 359, March 9, 2002
	12	"Determinants of the effectiveness of glucagon-like-peptide-1 in type 2 diabetes" by Toft-Nielsen et al, published J Clin Endocrinol Metab, 2001, Aug, 86(8):3863
	13	Co-pending application for Gerhardt et al., Serial No. 10/519,557, Filed 12/22/2004; Case No. F7649(V)

EXAMINER

DATE CONSIDERED

EXAMINER: INITIAL IF CITATION CONSIDERED. WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THOROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.